Coronavirus Disease 2019 (Covid-19) [Alpha/Beta] (Bivalent) Vaccine is under clinical development by SinoCelltech Group and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Coronavirus Disease 2019 (Covid-19) [Alpha/Beta] (Bivalent) Vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Coronavirus Disease 2019 (Covid-19) [Alpha/Beta] (Bivalent) Vaccine overview
The Vaccine candidate is a new generation of bivalent mutant strain recombinant protein vaccine. It contains the recombinant S trimeric protein antigens of the two major mutant strains alpha and beta. It is indicated to prevent diseases caused by novel coronavirus infection (COVID-19).
The vaccine candidate is under development for the prevention of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through intramuscular route. The vaccine candidate constitutes of coronavirus bivalent recombinant trimeric S (spike) protein.
SinoCelltech Group overview
SinoCelltech Group (SinoCelltech) is a biopharmaceutical and vaccine research and development company. The company’s activities include the development of biopharmaceuticals and vaccines. Its pipeline products include SCT800, SCT400, SCT400, SCT510, SCTV01, SCT-110A/PD-1, SCT1000/14, SCT650C/IL-17, SCTC21C/CD38 and SCTB35/CD20xCD3. SinoCelltech product indications include Hemophilia A, non-Hodgkin lymphoma, autoimmune disease, solid tumors, covid-19, solid and hematological tumors, cervical cancer, autoimmune disease, cd38-positive hematologic neoplasms and non-Hodgkin lymphoma. The company also carries out research and development activities in various diseases. SinoCelltech is headquartered in Beijing, China.
For a complete picture of Coronavirus Disease 2019 (Covid-19) [Alpha/Beta] (Bivalent) Vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.